Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Biotech tries everything it can in Nash
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
Madrigal changes the tune in Nash
A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Madrigal’s Maestro result puts the focus on Nash
Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
As Forte fails, who might yet improve the image of reverse mergers?
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
